Today, the 15 Support Group Leaders attending ASH with the IMF, were up at the crack of dawn—actually pre-dawn! We were on the 5:45 am shuttle with a long and exciting day ahead of us. First stop: We had a bird’s eye view (literally, see photo) of the IMF’s International Myeloma Working Group (IMWG) meeting. […]
The Messiah
Here I am at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. The atmosphere is electric; the schedule is hectic. I am jet-lagged and sleep deprived. I promised to report all the news about immunotherapy and drugs in the pipeline. Over the first two days, I attended the International […]
Day 2 at ASH 2015
Today’s events began with 7:30 am oral presentations on multiple myeloma therapies (excluding transplants, which came later in the afternoon). Highlights from the oral presentation during the day included: Revilmid®/VELCADE®/dexamethasone (RVd) + Panobinostat (Pano) for newly diagnosed patients (remember, Pano is only approved for relapsed patients) demonstrated a 46% near complete response (nCR) / complete […]
News about Myeloma Treatment Advances Has Been Heartening
Well, I survived the first day and half here at ASH. This is my second time to attend, and the advances in treatment have been great since my last attendance. We have three new treatments approved in a matter of weeks: Darzalex (daratumumab), Ninalor (ixazomib), and Empliciti (elotuzumab) as well as more on the way. […]
Looking Forward to Good Things for Patients with Relapsed/Refractory Myeloma!
Today is only half over, and we’ve already heard fantastic presentations. I’ll focus on just two of them here and direct you to the other leader’s blogs for a full picture of this jam-packed day of oral presentations, a scientific program, and much more. Eloquent-2 Update, a Phase 3, randomized, open-label study of Empliciti (elotuzumab) […]
Global Advances in Multiple Myeloma Treatments
One thing that never seems to change with multiple myeloma is that nothing is black or white. There are more shades of gray than one can imagine. The more answers we get the more questions we have. That became quickly evident at our first major event on Friday, the IMF Symposium addressing Global Advances in […]